ZIOPHARM Oncology, Inc. Release: Preclinical Darinaparsin Study in PLoS ONE Publication

NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today the publication of a darinaparsin (Zinapar® or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science. The publication, titled “Darinaparsin Is a Multivalent Chemotherapeutic Which Induces Incomplete Stress Response with Disruption of Microtubules and Shh Signaling,” was conducted by a Vanderbilt University Medical Center research team from the Departments of Cell and Developmental Biology, the Epithelial Biology Center, and Department of Surgery.